Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-69
SponsorGerman Heart Institute

About this trial

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( \> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.

The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

Eligibility criteria

Qualifiers

chronic diabetes mellitus (known/diagnosed and/or antidiabetic medication and/or elevated HbA1C) and/or

renal impairment (known/diagnosed CKD and/or in laboratory CKD III° or higher) and/or

Hypertension (known/diagnosed and/or antihypertensive medication/treatment) and/or

Hypercholesterolaemia (known/diagnosed and/or antilipid medication/treatment) and/or

Disqualifiers

Inability to provide written informed consent

Diagnosed heart failure or previously detected reduced ejection fraction

General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)

Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

600 Participants
are grouped into 1 trial group

Sponsors and collaborators

German Heart Institute

Lead sponsor

AstraZeneca

Collaborator

Philips Healthcare

Collaborator

Deutsches Herzzentrum der Charité, Berlin

Collaborator

German Heart Center Foundation

Collaborator

Nationale Herzallianz (NHA)

Collaborator

Deutsche Herzstiftung

Collaborator